**Maze Therapeutics Reports Financial Results for 2025, Provides Business Update**
Maze Therapeutics, Inc., a clinical-stage biopharmaceutical company, released its financial results for the year ended December 31, 2025. The company reported a net loss of $131.1 million, compared to a net income of $52.2 million for the year ended December 31, 2024. The shift from net income to net loss was primarily attributed to the absence of license revenue in 2025, as the company recognized $167.5 million in license revenue in 2024 from agreements with Shionogi & Co., Ltd., Trace Neuroscience, Inc., and Neurocrine Biosciences, Inc. As of December 31, 2025, Maze Therapeutics held $360.0 million in cash, cash equivalents, and marketable securities.
Operating expenses for 2025 totaled $142.9 million, an increase from $109.9 million in 2024. Research and development expenses rose to $108.4 million, driven by increased personnel-related costs, clinical trial expenses for MZE829 and MZE782, and higher manufacturing expenses. General and administrative expenses also increased to $34.5 million, reflecting higher personnel costs and public company expenses. Interest and other income, net, increased to $11.8 million, primarily due to higher cash balances from the company's initial public offering and private placement.
Operationally, Maze Therapeutics continued to advance its pipeline, with MZE829, an APOL1 inhibitor for AMKD, progressing into a Phase 2 trial. The company also reported positive topline clinical proof of concept data from this trial in March 2026. MZE782, targeting PKU and CKD, completed a Phase 1 clinical trial, and the company plans to initiate two Phase 2 trials in 2026. The company also highlighted its partnered program, MZE001 (S606001), for Pompe disease, which is in Phase 2 development under Shionogi. As of December 31, 2025, the company employed 141 full-time employees, with 108 dedicated to research and development activities.
Looking ahead, Maze Therapeutics anticipates that its existing cash, cash equivalents, and marketable securities will fund operations for at least one year. The company expects research and development expenses to increase as it continues to advance its clinical programs and expand its pipeline. The company also plans to leverage its Compass platform to identify new therapeutic targets and expand its precision medicine pipeline. The company has entered into a $200 million loan and security agreement with Hercules Capital, Inc. and may elect to issue and sell shares of its common stock having an aggregate offering price of up to $200.0 million through Jefferies LLC.
About Maze Therapeutics, Inc.
Maze Therapeutics is a biopharmaceutical company focused on developing precision medicines for renal, cardiovascular, and metabolic diseases. Using its proprietary Compass platform, it identifies genetic variants linked to disease and creates targeted small molecule therapies. Its pipeline includes treatments for chronic kidney disease, especially APOL1-related kidney disorders, aiming to address underlying genetic drivers and improve patient outcomes through innovative, genetically informed drug development.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.